Windlas Biotech Limited, one of the leading domestic pharmaceutical formulations contract development and manufacturing organization (“CDMO”) industry in India, has received certificate of Good Manufacturing Practices (GMP) from SAHPRA (South African Health Products Regulatory Authority). The company had undergone the inspection audit from 20th to 29th September 2021.
Recently, the company concluded EU GMP inspection with zero critical observations and deficiencies. This we believe is a testimony of company’s quality standards and capabilities. The company’s growth trajectory is expected to accelerate further, in the upcoming quarters underpinned by the geographic expansion for CDMO and Exports Vertical driven by the positive regulatory audit outcomes”.